LGND Ligand Pharmaceuticals Earnings and EPS analysis

Relative Growth: Rel. Growth: 95

Relative Strength: Rel. Strength: 86

Relative Valuation: Rel. Valuation: 54

Relative Profitability: Rel. Profitability: 98

EPS in 2026 (TTM): $10.07

Last Report Period Date: Jun 30, 2026

According to the most recent financial data from June 2026, the current EPS (TTM) is $10.07. Ligand Pharmaceuticals's EPS for 2025 came in at $6.44, marking an increase from -$0.22 in 2024. For the quarterly period ending on Jun 30, 2026, LGND's EPS was $2.42.

LGND earnings history

Historical annual and quarterly earnings per share (EPS) data for Ligand Pharmaceuticals

EPS (TTM)

$10.07

EPS Growth YoY (Quarterly)

868%

EPS (Quarterly)

$2.42

EPS Growth (Quarterly)

461.2%

Ligand Pharmaceuticals had an annual EPS of $6.44, marking an increase of 3,027.3% from -$0.22 in 2024. The quarterly EPS for the period ending Jun 30, 2026, was $2.42, marking a 868% increase from the same quarter last year. LGND's TTM EPS stands at $10.07 as of June 2026. Ligand Pharmaceuticals's EPS for 2024 stood at -$0.22, a 107.3% decrease from 2023.

LGND EPS vs price chart

LGND EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

868%

EPS growth YoY

3,027.3%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Ligand Pharmaceuticals has recorded an increase in EPS of 868% over the last 12 months (YoY, quarterly). Across the last decade, LGND had an average annual EPS growth of -5.7%.

LGND Earnings Waterfall

Breakdown of revenue, profit and net income for Ligand Pharmaceuticals

LGND Earnings vs Peers

What are the earnings of LGND compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
BMY Bristol-Myers Squibb Company	13.99	178.7%	5.3%	N/A
AMGN AMGEN Inc	23.26	88.1%	5.6%	2.9%
LGND Ligand Pharmaceuticals Inc - Class B	28.25	3,027.3%	N/A	N/A
JNJ Johnson & Johnson	30.42	90.6%	17.7%	14.8%
PFE Pfizer Inc	36.47	-3.5%	-37.4%	-3.7%
LLY Lilly(Eli) & Company	37.39	95.6%	49.2%	27.5%
MRK Merck & Co Inc	113.33	8%	8.4%	21.2%
BAX Baxter International Inc	N/A	-47.2%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.